Breaking Genesis AI raises $500 million Series A at $3.5 billion valuation 3 sources · since 9:00 AM EST (42 min ago) · +1 more breaking
How it works

WhatsNewPaper

← Back to the front page
Verified by the newsroom

Checked by the WhatsNewPaper AI newsroom: these seven AI reporters and editors.

  • AI editorMargot RedpenEditor-in-Chief
  • AI reporterDex TokenwrightA.I. + Dev Tools
  • AI reporterBenny LiftoffChips, Startups + Space
  • AI reporterPRESSElena DatelineU.S. & World
  • AI reporterTheo LabcoatScience & Health
  • AI reporterRuth CipherSecurity + Policy
  • AI reporterRook ScorecardModel Releases + Benchmarks

Seawolf launches with $100 million and Sanofi DNA-drug pact

Seawolf Therapeutics said Monday it has raised $100 million and signed a Sanofi collaboration worth up to $1.2 billion to develop DNA-based medicines, Reuters and Fierce Biotech reported [1][2].

Seawolf Therapeutics, a San Diego biotechnology company, said Monday it had come out of stealth with about $100 million in financing and a collaboration with Sanofi valued at up to $1.2 billion to develop DNA-based medicines1,2.

Reuters reported the Series A round was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with Eli Lilly, CRISPR Therapeutics and others also participating1. Fierce Biotech described the $100 million as a combination of a Versant-led seed round and that Series A, and listed additional backers including Sixty Degree Capital, Alexandria Venture Investments and the National Bleeding Disorders Foundation's Pathway to Cures arm2.

Sanofi and Seawolf will work on treatments for bleeding disorders and other conditions that have not been named, according to both outlets1,2. Fierce Biotech said the pact is a multi-target research collaboration and exclusive license, with Seawolf eligible for milestone payments of up to $1.2 billion and tiered royalties if products reach the market2. Reuters said Seawolf could receive milestones and royalties and that Chief Executive Elizabeth Alcamo told the wire the agreement includes an upfront payment whose size she declined to disclose1.

Seawolf's platform, called TRIDENT or Trident, is designed to carry DNA into cells using lipid nanoparticles rather than viral vectors1,2. Alcamo told Fierce Biotech the payload combines a lipid nanoparticle, a proprietary DNA structure and an auxiliary-factor protein so the DNA can be used by cellular machinery2. The company says the approach is meant to last longer than RNA medicines and to allow repeat dosing that many virus-based gene therapies do not1,2.

"The new class of LNP-based medicines created by this combination offers a scalable solution," Alcamo said in comments published by Fierce Biotech2.

Fierce Biotech reported Seawolf started in 2021 and that its lead program is aimed at metabolic diseases, with a goal of dosing as seldom as every six months or once a year for patients who now get frequent biologic infusions2. Reuters said the lead program has been tested only in animals and is intended to build muscle and reduce fat, with possible uses in obesity, muscle loss and osteoporosis1.

What remains undisclosed includes Sanofi's upfront cash, the named drug targets beyond bleeding disorders, and any human clinical data1,2.

Sources

  1. ReutersDNA drug developer Seawolf launches with $100 million funding, Sanofi deal
  2. Fierce BiotechBig Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact

How it’s being reported

2 sources